Leerink Partners Has Lowered Expectations for Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price

Recursion Pharmaceuticals (NASDAQ:RXRX) had its price objective dropped by stock analysts at Leerink Partners from $7.00 to $6.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. Leerink Partners’ price objective points to a potential downside of 20.11% from the stock’s current price.

A number of other brokerages have also recently weighed in on RXRX. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $7.51 on Friday. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $14.12. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business has a fifty day moving average of $7.72 and a two-hundred day moving average of $7.08. The company has a market cap of $2.93 billion, a P/E ratio of -4.91 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter in the prior year, the business earned ($0.42) EPS. The company’s quarterly revenue was down 57.8% compared to the same quarter last year. As a group, analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. Private Advisor Group LLC grew its holdings in Recursion Pharmaceuticals by 28.6% in the 3rd quarter. Private Advisor Group LLC now owns 15,419 shares of the company’s stock valued at $102,000 after buying an additional 3,432 shares during the period. International Assets Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 527.3% in the 3rd quarter. International Assets Investment Management LLC now owns 84,682 shares of the company’s stock valued at $558,000 after buying an additional 71,182 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Recursion Pharmaceuticals by 1,173.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,539 shares of the company’s stock valued at $611,000 after buying an additional 80,664 shares during the period. Finally, SteelPeak Wealth LLC grew its holdings in Recursion Pharmaceuticals by 310.0% in the 3rd quarter. SteelPeak Wealth LLC now owns 88,274 shares of the company’s stock valued at $582,000 after buying an additional 66,742 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.